Clinical Trials in Ancona, Italy
2 recruiting
Showing 1–14 of 14 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Breast CancerLung Cancer
Bristol-Myers Squibb416 enrolled63 locationsNCT06618287
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Renal Cell Carcinoma (RCC)
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1Phase 2
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Gastric CancerSolid Tumors
EMD Serono Research & Development Institute, Inc.250 enrolled81 locationsNCT06710132
Recruiting
Phase 2
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Advanced Breast CancerAdvanced Breast Carcinoma
MedSIR200 enrolled47 locationsNCT06486883
Recruiting
Phase 3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
Nuvalent Inc.450 enrolled112 locationsNCT06765109
Recruiting
Phase 1Phase 2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled214 locationsNCT07128199
Recruiting
Phase 3
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc.500 enrolled222 locationsNCT05696626
Recruiting
Phase 2
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Breast Cancer
BicycleTx Limited66 enrolled39 locationsNCT06840483
Recruiting
Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Summit Therapeutics1,600 enrolled244 locationsNCT05899608
Recruiting
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Metastatic Breast Cancer
European Institute of Oncology1,000 enrolled37 locationsNCT06994377
Recruiting
EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase
Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS1,000 enrolled29 locationsNCT06894173
Recruiting
Phase 2
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
HER2-positive Breast Cancer
GBG Forschungs GmbH170 enrolled29 locationsNCT05306041